Allogene Therapeutics (NASDAQ:ALLO) PT Lowered to $10.00 at HC Wainwright

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also issued reports about the company. Guggenheim lowered Allogene Therapeutics from a buy rating to a […]

Related Keywords

Deborahm Messemer , ,Citigroup ,Mcglone Suttner Wealth Management Inc ,Allogene Therapeutics Inc ,Victory Capital Management Inc ,Dorsey Whitney Trust ,Jpmorgan Chase Co ,Ep Wealth Advisors ,Nasdaq ,Allogene Therapeutics Company Profile ,Allogene Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Director Deborah ,Glone Suttner Wealth Management ,Capital Management ,Whitney Trust ,Allogene Therapeutics Daily ,Nasdaq Allo ,Allo ,Medical ,Lower Price Target ,Hc Wainwright ,